US patent secured for PromarkerEndo
Proteomics International secures US patent grant for endometriosis innovative diagnostic test
-
United States Patent and Trademark Office (USPTO) has granted a new patent for the PromarkerEndo proprietary blood test for the diagnosis of endometriosis
-
Major milestone with patent granted in the world’s largest healthcare market
-
The patent supports commercialisation efforts and underpins the commercialisation pathway, enabling future partnerships and licensing opportunities.
-
Published clinical data has demonstrated the patented blood test has high accuracy for diagnosing endometriosis, including in the early stages of the disease
-
Patent protection for the PromarkerEndo technology has now advanced in major jurisdictions including Japan and the United States
-
Global need - endometriosis affects one in nine women and currently diagnosis typically takes an average of 7 years
View ASX Announcement: here